← 返回前沿论文

局部单次放疗改善 TIL(肿瘤浸润淋巴细胞)过继细胞治疗

英文原题:Local Single-Dose Radiation Improves Adoptive Cell Therapy With Tumor-Infiltrating Lymphocytes.

查看英文原题

Local Single-Dose Radiation Improves Adoptive Cell Therapy With Tumor-Infiltrating Lymphocytes.

PubMed 2025/06/27(内容时间) Int J Radiat Oncol Biol Phys Q1 · IF 7.4(JCR 2025)

研究概要

在肿瘤切除前进行RT以增强TIL扩增,以及在ACT当天进行RT以促进T细胞浸润,这两个不同时间点的RT显著提高了ACT的疗效。这些发现凸显了将RT与ACT联合使用以改善转移性疾病治疗效果的潜力。

研究思路结论见上方概要

放射治疗(RT)增强肿瘤反应性T细胞过继细胞治疗(ACT)的潜力尚未得到充分探索。本研究评估了RT与ACT的联合应用,在两个关键时间点施加RT:(1)肿瘤切除前,以改善TIL(肿瘤浸润淋巴细胞)的体外扩增;(2)在ACT当天使用抗原特异性T细胞,以增强转移后的T细胞浸润。

使用鼠源HPV阳性头颈部鳞状细胞癌(HNSCC)模型,我们在肿瘤切除前5天给予单次剂量RT(8 Gy 1)。进行RNA测序以检测RT后趋化因子的表达。将肿瘤碎片在白细胞介素-2(IL-2)中培养以扩增TIL,并通过细胞因子产生试验评估TIL反应性。对荷瘤小鼠使用来自未治疗或RT治疗肿瘤扩增的TIL进行ACT治疗。在额外实验中,我们评估了RT联合ACT是否能改善T细胞浸润和抗肿瘤活性。

RT预处理显著增强了离体TIL扩增(96% vs 74%;P < .05),并增加了肿瘤坏死因子(TNF-)的产生(P = .03),表明反应性改善。RT还显著增加了TNF- + GzmB + CD8 + TIL的扩增(P = .02),表明细胞毒性亚群内的多功能性增强。RNA测序显示趋化因子(如CCL21和CXCL10)及其受体(CCR7和CXCR4)上调,支持TIL募集增强。使用来自RT预处理肿瘤的TIL进行ACT显示出优越的肿瘤控制,50%的小鼠实现完全肿瘤消退(CR),而对照组为12.5%。与仅接受ACT或RT的小鼠相比,在ACT当天进行RT增加了T细胞向肿瘤的浸润并改善了肿瘤排斥。

展开英文摘要原文

INTRODUCTION: The potential for radiation therapy (RT) to enhance adoptive cell therapy (ACT) with tumor-reactive T cells has not been fully explored. This study evaluated combining RT with ACT, applying RT at two critical time points: (1) before tumor resection to improve ex vivo expansion of tumor-infiltrating lymphocytes (TIL) and (2) on the day of ACT using antigen-specific T cells to enhance T cell infiltration after transfer. METHODS AND MATERIALS: Using a murine human papillomavirus (HPV)-positive head and neck squamous cell carcinoma (HNSCC) model, we administered single-dose RT (8 Gy 1) 5 days before tumor resection. RNA sequencing was performed to measure chemokine expression post-RT. Tumor fragments were cultured in interleukin-2 (IL-2) for TIL expansion, and TIL reactivity was assessed through cytokine production assays. Tumor-bearing mice were treated with ACT with TIL expanded from untreated or RT-treated tumors. In additional experiments, we assessed whether RT given in combination with ACT could improve infiltration of T cells and antitumor activity. RESULTS: RT preconditioning significantly enhanced ex vivo TIL expansion (96% vs 74%; P < .05) and increased tumor necrosis factor (TNF- ) production (P = .03), indicating improved reactivity. RT also significantly increased the expansion of TNF- + GzmB + CD8 + TILs (P = .02), suggesting enhanced polyfunctionality within a cytotoxic subset. RNA sequencing revealed upregulation of chemokines (eg, CCL21 and CXCL10) and their receptors (CCR7 and CXCR4), supporting enhanced TIL recruitment. ACT with TIL from RT-preconditioned tumors demonstrated superior tumor control, with 50% of mice achieving complete tumor regression (CR) compared with 12.5% in controls. RT on the day of ACT increased T cell infiltration into tumor and improved tumor rejection compared with mice receiving either ACT or RT alone. CONCLUSIONS: RT at two distinct time points-before tumor resection to enhance TIL expansion and on the day of ACT to boost T cell infiltration-significantly improves the efficacy of ACT. These findings highlight the potential for combining RT with ACT to enhance therapeutic outcomes in metastatic disease.

论文信息

作者
Obertopp N、Bekker RA、Grass GD、Zelenka T、Thomas A、Potez M、Ali J、Blauvelt J
第一作者单位
Department of Immunology, H. Lee Moffitt Cancer Center &amp; Research Institute, Tampa, Florida; Cancer Biology Ph.D. Program, University of South Florida, Tampa, Florida.United States
通讯作者单位
Department of Immunology, H. Lee Moffitt Cancer Center &amp; Research Institute, Tampa, Florida. Electronic address: shari.pilon-thomas@moffitt.org.United States
文献类型
美国 NIH 资助研究
期刊
International journal of radiation oncology, biology, physics2025 Nov 15
原文标识
PubMed 40582598 · DOI 10.1016/j.ijrobp.2025.06.3856